Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Commercial Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IOVANCE BIOTHERAPEUTICS, INC.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 156,947 |
Reported balance
After 2026-08-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-10 · Exercise / conversion · Acquired 10,001 · Balance 156,947 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 154,511 |
Reported balance
After 2026-08-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-10 · Tax withholding · Disposed 2,436 · Balance 154,511 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents the common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 60,003 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 10,001 · Balance 60,003 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents the common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-095040 · tm2622903-1_4seq1.xml · derivative · entry 3 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,003 Underlying: Common Stock · 10,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,436 | $6.40 | $15,590.40 |
DisclosureSEC source: 0001104659-26-095040 · tm2622903-1_4seq1.xml · nonDerivative · entry 2 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,511 F2 · date: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 10,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-095040 · tm2622903-1_4seq1.xml · nonDerivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| May 11, 2026 Filed May 13, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-060356 · tm2614425-1_4seq1.xml · derivative · entry 3 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,004 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| May 11, 2026 Filed May 13, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 2,435 | $3.70 | $9,009.50 |
DisclosureSEC source: 0001104659-26-060356 · tm2614425-1_4seq1.xml · nonDerivative · entry 2 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,946 F2 · date: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| May 11, 2026 Filed May 13, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-060356 · tm2614425-1_4seq1.xml · nonDerivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 132,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-026444 · tm268453-2_4seq1.xml · derivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,200 Underlying: Common Stock · 132,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-020613 · tm267318-1_4seq1.xml · derivative · entry 3 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: On February 10, 2025, the Reporting Person was granted an award of up to 150,000 PSUs, which vests in the form of shares of the Issuer's common stock upon the achievement of certain financial milestones. On February 24, 2026, certain financial milestones were met, resulting in the vesting of the PSUs as to 120,000 of the underlying shares and the cancellation of the PSUs as to 30,000 of the underlying shares. F5 · derivative.expiration_date: On February 10, 2025, the Reporting Person was granted an award of up to 150,000 PSUs, which vests in the form of shares of the Issuer's common stock upon the achievement of certain financial milestones. On February 24, 2026, certain financial milestones were met, resulting in the vesting of the PSUs as to 120,000 of the underlying shares and the cancellation of the PSUs as to 30,000 of the underlying shares. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 34,165 | $3.78 | $129,143.70 |
DisclosureSEC source: 0001104659-26-020613 · tm267318-1_4seq1.xml · nonDerivative · entry 2 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,381 F2 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the PSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-020613 · tm267318-1_4seq1.xml · nonDerivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of shares of the Issuer's common stock underlying performance-based restricted stock units ("PSUs") that have been earned based on the level of achievement of certain financial milestones. The earned PSUs vested on February 24, 2026. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 39,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-014400 · tm266006-1_4seq1.xml · derivative · entry 3 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,004 Underlying: Common Stock · 39,996 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on February 10, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 16,450 | $2.60 | $42,770.00 |
DisclosureSEC source: 0001104659-26-014400 · tm266006-1_4seq1.xml · nonDerivative · entry 2 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,546 F2 · date: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents the common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 39,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-014400 · tm266006-1_4seq1.xml · nonDerivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 30,000 | $1.84 | $55,200.00 |
DisclosureSEC source: 0001104659-25-057310 · tm2517335-1_4seq1.xml · nonDerivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Shares were acquired in the open market during a permitted trading window in accordance with the Issuer's Insider Trading Policy. A copy of the Insider Trading Policy is filed as Exhibit 19.1 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantPerformance Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-012273 · tm256127d2_4seq1.xml · derivative · entry 3 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires not disclosed F3 · derivative.exercise_price: Each performance stock unit ("PSU") converts into one share of the Issuer's common stock. F4 · shares: Up to 150,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain financial milestones. F5 · derivative.exercise_date: Such earned PSUs shall vest on the date that the Issuer publicly announces its 2025 financial results by filing its Form 10-K with the U.S. Securities and Exchange Commission. F5 · derivative.expiration_date: Such earned PSUs shall vest on the date that the Issuer publicly announces its 2025 financial results by filing its Form 10-K with the U.S. Securities and Exchange Commission. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-012273 · tm256127d2_4seq1.xml · derivative · entry 2 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common stock · 120,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F1 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Options (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001104659-25-012273 · tm256127d2_4seq1.xml · derivative · entry 1 Kirby Daniel Gordon · CIK 0002055001 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common stock · 35,000 shares Expires 2035-02-10 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.